Omeros (NASDAQ:OMER) Stock Price Down 6.8% - Here's Why

Key Points

• Omeros shares fell about 6.8% intraday to $8.86 on Tuesday, with roughly 1.56 million shares traded versus an average session volume of 1.63 million and a prior close of $9.51.
• Analyst views are mixed — ratings range from sell to strong-buy, with MarketBeat showing an average rating of Moderate Buy and an average price target of $33.67.
• The company beat quarterly EPS estimates (reported ($0.19) vs. ($0.58) expected) but analysts still forecast a -3.09 EPS for the fiscal year; Omeros has a market cap of ~$618 million and a negative P/E (-4.33).

Omeros Corporation (NASDAQ:OMER - Get Free Report)'s share price traded down 6.8% during mid-day trading on Tuesday . The company traded as low as $8.90 and last traded at $8.8640. 1,556,557 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 1,626,800 shares. The stock had previously closed at $9.51.

Analyst Upgrades and Downgrades

OMER has been the subject of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Omeros in a report on Wednesday, October 8th. WBB Securities reissued a "strong-buy" rating and set a $45.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Wednesday, October 15th. Wall Street Zen upgraded shares of Omeros from a "sell" rating to a "hold" rating in a report on Saturday, December 13th. Finally, D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Omeros currently has an average rating of "Moderate Buy" and an average price target of $33.67.

Omeros Stock Down 8.4%

The firm has a fifty day moving average price of $8.62 and a two-hundred day moving average price of $5.56. The stock has a market capitalization of $617.89 million, a P/E ratio of -4.33 and a beta of 2.48.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39. Sell-side analysts anticipate that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

A number of large investors have recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. bought a new stake in Omeros during the 2nd quarter valued at $32,000. Harbour Investments Inc. lifted its holdings in shares of Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 4,251 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 11,971 shares during the last quarter. Sei Investments Co. acquired a new stake in shares of Omeros during the second quarter worth $40,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 5,677 shares during the last quarter. Institutional investors own 48.79% of the company's stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.